Control Group (N = 12) | NAFLD Group (N = 22) | P Value* | NAFLD-No Fibrosis Group (N = 11) | P Value* | NAFLD-Fibrosis Group (N = 11) | P Value* | |
---|---|---|---|---|---|---|---|
AUC0–12 (ng/ml × h) | 25.4 ± 11.0 | 20.1 ± 14.3 | 0.28 | 21.5 ± 13.5 | 0.46 | 18.6 ± 15.7 | 0.25 |
AUC0–∞ (ng/ml × h) | 30.7 ± 13.6 | 25.4 ± 17.0 | 0.35 | 27.0 ± 15.4 | 0.58 | 23.7 ± 19.2 | 0.36 |
Cmax (ng/ml) | 3.7 ± 2.0 | 3.0 ± 2.6 | 0.42 | 3.3 ± 2.6 | 0.70 | 2.8 ± 2.7 | 0.39 |
Tmax (h) | 3.9 ± 2.0 | 3.8 ± 1.9 | 0.86 | 3.7 ± 2.1 | 0.81 | 3.9 ± 1.8 | 0.95 |
t1/2 (h) | 4.4 ± 1.2 | 5.4 ± 2.9 | 0.21 | 4.8 ± 1.4 | 0.54 | 6.0 ± 4.0 | 0.25 |
Xurine,0–12 (μg) | 257 ± 107 | 209 ± 186 | 0.34 | 244 ± 230 | 0.87 | 174 ± 130 | 0.11 |
CLrenal (ml/min) | 180 ± 64 | 178 ± 69 | 0.93 | 178 ± 84 | 0.94 | 178 ± 53 | 0.94 |
↵* Two-tailed, t test or χ2 test with comparison with control group.